Anti-Tumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed Glioblastoma Multiforme During Recovery From Therapeutic Temozolomide-Induced Lymphopenia.

Trial Profile

Anti-Tumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed Glioblastoma Multiforme During Recovery From Therapeutic Temozolomide-Induced Lymphopenia.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 26 May 2017

At a glance

  • Drugs Cancer vaccine-pp65 (Primary) ; Autolymphocyte therapy; Temozolomide
  • Indications Glioblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ATTAC
  • Most Recent Events

    • 22 May 2017 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
    • 22 May 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.
    • 15 Apr 2017 Results (n=11) assessing safety and efficacy, published in the Clinical cancer research: an official journal of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top